Sariya Banday: Optimizing BCMA CAR-T Cells to Improve Persistence and Reduce Exhaustion
Sariya Banday, Executive Board Member at University of Minnesota Rural Health Advocacy Network, shared a post on LinkedIn:
“I’m excited to share that my first-author abstract, ‘Nicotinamide and Vitamin C conditioning preserves an early-memory phenotype and limits exhaustion in BCMA CAR-T cells,’ has been accepted for poster presentation at the 2026 ASH Annual Meeting in New Orleans and received an ASH Abstract Achievement Award!
Over the summer I conducted research at the Medical College of Wisconsin Center for Cancer Discovery where I looked for ways to help BCMA CAR-T cells persist and resist exhaustion in multiple myeloma.
Through much determination, trial and error, and hard work, we successfully found that conditioning the cells with Vitamin C and Nicotinamide helped preserve an early-memory phenotype while limiting cell exhaustion.
I would like to extend my gratitude towards Sun, Rai, and everyone in lab for their guidance throughout this project.
Their mentorship made this possible.
I will be presenting on Sunday, December 13 in Hall F and if you are attending ASH, please stop by and say hello!”
Stay updated with Hemostasis Today.
-
Nov 11, 2026, 13:52Vera Ignjatović: The Changing Balance of Hemostasis Across Childhood
-
Nov 11, 2026, 13:46Danny Gaskin: Recognising Iron Deficiency Before Anaemia
-
Nov 11, 2026, 13:46James P. Crowley: Newborn Vitamin K Refusal a 347% Surge in Life-Threatening Bleeding
-
Nov 11, 2026, 13:42Manideepa Maji: IV Iron Safety in Heart Failure
-
Nov 11, 2026, 13:36Wilson Andrés Vásconez Samaniego: NGS-Based Genomic Profiling Before Gene Therapy for Hemoglobinopathies
-
Nov 11, 2026, 13:34Mathieu Jackson: WFH Opens Registration for 2027 Comprehensive Care Summit
-
Nov 11, 2026, 13:29Maia Meier: Recognising Bleeding Disorders Through the 7-2-1 Rule
-
Nov 11, 2026, 13:17Kiran Rajeev T: Elsevier Releases New Practical Handbook on Transfusion Medicine
-
Nov 11, 2026, 13:01Reza Shojaei: FDA Approval Marks Milestone for Factor XIa-Targeted Therapy